Enhancing the QUAlity and Transparency Of health Research
Use your browser's Back button to return to your search results
|Reporting guideline provided for?
(i.e. exactly what the authors state in the paper)
|Reporting of vaccine quantitative benefit-risk model (qBRm) research.|
|Full bibliographic reference||Arlegui H, Bollaerts K, Bauchau V, Nachbaur G, Bégaud B, Praet N. Benefit-Risk Assessment of Vaccines. Part II: Proposal Towards Consolidated Standards of Reporting Quantitative Benefit-Risk Models Applied to Vaccines (BRIVAC). Drug Saf. 2020;1-16.|
(full-text if available)
|The full-text of the BRIVAC reporting guideline is available at: https://link.springer.com/article/10.1007%2Fs40264-020-00982-9
The BRIVAC checklist can be accessed at: https://link.springer.com/article/10.1007/s40264-020-00982-9/tables/2
|Reporting guideline acronym||BRIVAC|
|Clinical area||Infectious diseases, Pharmaceutical medicine, Public health|
|Applies to the whole report or to individual sections of the report?||Whole report|
|Record last updated on||October 2, 2020|
Some reporting guidelines are also available in languages other than English. Find out more in our Translations section.